Virtu KCG Holdings’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Virtu KCG Holdings’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$479K	Buy	19,909 +6,580	+49%	+$147K	0.01%	1186
2017 Q1	$309K	Buy	+13,329	New	+$283K	0.01%	1917
2016 Q2	–	Sell	-11,163	Closed	-$213K	–	2939
2016 Q1	$213K	Sell	11,163 -50,868	-82%	-$986K	0.01%	2040
2015 Q4	$1.8M	Buy	62,031 +47,464	+326%	+$1.37M	0.03%	470
2015 Q3	$384K	Sell	14,567 -16,708	-53%	-$565K	0.01%	1806
2015 Q2	$1.13M	Buy	+31,275	New	+$1.08M	0.02%	752
2015 Q1	–	Sell	-41,727	Closed	-$1.16M	–	3137
2014 Q4	$1.16M	Buy	+41,727	New	+$1.14M	0.02%	818

Other funds holding BBC

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CCP

Cardan Capital Partners Denver, Colorado $893M AUM 22.82% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtu KCG Holdings's BBC Position: Q2 2017 in Review

Virtu KCG Holdings increased its Virtus Biotech Clinical Trials ETF (BBC) stake by 49% in Q2 2017, buying an estimated $147K and bringing the position to 19,909 shares worth $479K. The position accounts for 0.01% of the portfolio, ranked #1186.

Virtu KCG Holdings first reported a position in BBC in Q4 2014 and has held it in 7 quarters since. The position peaked at $1.8M in Q4 2015. 18 funds tracked by Wall St. Rank hold BBC as of Q2 2017.

Virtu KCG Holdings held 19,909 shares of Virtus Biotech Clinical Trials ETF worth $479K as of Q2 2017.
Virtu KCG Holdings bought 6,580 Virtus Biotech Clinical Trials ETF shares in Q2 2017, an estimated $147K.
Virtus Biotech Clinical Trials ETF made up 0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #1186 holding.
Virtu KCG Holdings first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2014 and has held it in 7 quarters since.
Virtu KCG Holdings's Virtus Biotech Clinical Trials ETF position peaked at $1.8M in Q4 2015.
18 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.